Pioneering GIP
receptor antagonism for obesity treatment

We’re addressing obesity and overweight through GIP receptor antagonism, developing treatments that go beyond weight loss to deliver long-term sustained health, without compromising on tolerability.

Pipeline

A first-in-human, single ascending dose (SAD)/multiple ascending dose (MAD) study of AT-7687 was successfully concluded in Q4 2025. AT-7687 is currently being evaluated in combination with semaglutide in a phase 2a study in patients with obesity and type 2 diabetes.

Preclinical Studies
Phase 1
Phase 2
AT7687
+ GLP-1A
AT7687 1x weekly
Obesity with Type 2 Diabetes
AT7687 1x monthly
Feasibility studies
AT7687
+ amylin
AT7687 1x weekly
PoC study finalized

← Scroll to see the whole diagram →